Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis.
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
05
10
2023
accepted:
26
12
2023
medline:
13
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
epublish
Résumé
Quality of life impairment in dermatology patients and severity of psoriasis are quantified by the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI), respectively. The aim of this study is to compare the correlation between PASI and DLQI in patients from different geographical areas and to identify predictors of high DLQI across geographical regions. Correlations between PASI and DLQI were evaluated using Spearman's rank correlation tests and quantile regression. The study included 1,158 patients with psoriasis, with a median (interquartile range) PASI and DLQI of 6.0 (3.0-12.0) and 8.0 (4.0-15.0), respectively. Correlations were demonstrated between PASI and DLQI, both overall and stratified by geographical region. Quantile (median) regression yielded coefficients of 0.75 (95% confidence interval (95% CI) 0.62, 0.88) for Switzerland, 0.50 (95% CI 0.42, 0.58) for Latin America, 0.34 (95% CI 0.16, 0.51) for Asia, and 0.31 (95% CI 0.08, 0.53) for the USA. Current age, age at diagnosis, sex, body mass index, and psoriasis arthritis affected DLQI in Latin America, while education had an impact among patients treated in Switzerland. Few countries were included within each continent; hence, more data from different countries are necessary for generalizability. The study showed correlations between PASI and DLQI among patients in all included geographical regions. The patients' characteristics affecting DLQI vary worldwide.
Identifiants
pubmed: 38470165
doi: 10.2340/actadv.v104.20329
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv20329Références
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317
pubmed: 33547728
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Dermatol Ther. 2022 Aug;35(8):e15653
pubmed: 35731640
Front Med (Lausanne). 2021 Dec 16;8:743180
pubmed: 34977058
JAMA. 2006 Oct 11;296(14):1735-41
pubmed: 17032986
Clin Exp Dermatol. 2022 Dec;47(12):2234-2241
pubmed: 35988043
Acta Derm Venereol. 2019 Dec 1;99(13):1224-1230
pubmed: 31580465
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7
pubmed: 23425140
J Am Acad Dermatol. 2020 Jan;82(1):117-122
pubmed: 31425723
J Am Acad Dermatol. 2016 Jul;75(1):77-82.e7
pubmed: 27206759
J Dermatolog Treat. 2017 Dec;28(8):731-736
pubmed: 28489479
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Dermatol Ther. 2020 Nov;33(6):e14337
pubmed: 32974992
J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19
pubmed: 29928910
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Arch Dermatol Res. 2016 Mar;308(2):69-78
pubmed: 26688112
Br J Dermatol. 2021 Dec;185(6):1160-1168
pubmed: 33837519
Psoriasis (Auckl). 2022 May 24;12:99-112
pubmed: 35637943
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):213-220
pubmed: 27739123
Life (Basel). 2022 Sep 10;12(9):
pubmed: 36143449
J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7
pubmed: 10459113
J Invest Dermatol. 2007 Oct;127(10):2315-22
pubmed: 17495953
Br J Dermatol. 2023 Mar 30;188(4):533-541
pubmed: 36653920
Br J Dermatol. 2015 Aug;173(2):510-8
pubmed: 25989336
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498
pubmed: 33349983
Dermatol Ther (Heidelb). 2021 Aug;11(4):1373-1384
pubmed: 34110605
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708
pubmed: 30388318